Esperion Therapeutics Stock News

Needham analyst Chad Messer reiterated a Buy rating on Esperion (ESPR – Research Report) today and set a price target

JMP Securities analyst Jason Butler reiterates an

After Needham and Merrill Lynch gave Esperion (NASDAQ: ESPR) a Buy rating last month, the company received another Buy, this time from Stifel Nicolaus.

After Needham and Merrill Lynch gave Esperion (NASDAQ: ESPR) a Buy rating last month, the company received another Buy, this

JMP reiterates $191 price target on Esperion after Japan partnership JMP Securities ESPR

Northland Securities analyst Carl Byrnes maintained a Hold rating on Esperion (ESPR) today and set a price target of $42.00. The company's shares closed

Northland Securities analyst Carl Byrnes maintained a Hold rating on Esperion (ESPR – Research Report) today and set a price

Esperion, Otsuka Pharmaceutical sign deal for NEXLETOL, NEXLIZET in Japan ESPR

Esperion (ESPR) today announced that they have entered into a collaboration agreement with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of NEXLETOL and NEXLIZET tablets in

We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was

We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was

We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was

Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted